BCL2 and B-cell chronic lymphocytic leukemia: Pirtobrutinib and nemtabrutinib, reversible (noncovalent) BTKis, are under investigation for chronic lymphocytic leukemia1,2; pirtobrutinib was granted accelerated approval by the FDA for patients with CLL/small lymphocytic lymphoma who have received at least 2 prior lines of therapy, including a BTKi and a B-cell lymphoma (BCL)-2 inhibitor.